Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United StatesAnuja Chatterjee, Matthew S. Davids, Gijs van de Wetering et al.|Journal of Managed Care & Specialty Pharmacy|2021Cited by 20
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United StatesSang Kyu Cho, Scott Johnson, Beenish S. Manzoor et al.|PharmacoEconomics|2020Cited by 19
Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United StatesMatthew S. Davids, Michael Hallek, Gijs van de Wetering et al.|Blood|2019Cited by 11